Posted by Michael Wonder on 25 Mar 2022
Bristol Myers Squibb announces new Prescription Drug User Fee Act goal date for Reblozyl (luspatercept-aamt) supplemental biologics license application
25 March 2022 - Bristol Myers Squibb today announced that the U.S. FDA has extended the review of the supplemental biologics license application for Reblozyl (luspatercept-aamt) for the treatment of anaemia in adults with non-transfusion-dependent beta thalassaemia to 27 June 2022.
Reblozyl is being developed and commercialised through a global collaboration with Merck following Merck’s acquisition of Acceleron Pharma in November 2021.
